MX360161B - Proceso para preparar compuestos antiviricos. - Google Patents

Proceso para preparar compuestos antiviricos.

Info

Publication number
MX360161B
MX360161B MX2015002251A MX2015002251A MX360161B MX 360161 B MX360161 B MX 360161B MX 2015002251 A MX2015002251 A MX 2015002251A MX 2015002251 A MX2015002251 A MX 2015002251A MX 360161 B MX360161 B MX 360161B
Authority
MX
Mexico
Prior art keywords
antiviral compounds
compounds
salts
preparing antiviral
preparing
Prior art date
Application number
MX2015002251A
Other languages
English (en)
Other versions
MX2015002251A (es
Inventor
M Barnes David
R Haight Anthony
Shekhar Shashank
S Franczyk Thaddeus
B Dunn Travis
S Chan Vincent
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/591,117 external-priority patent/US8975443B2/en
Priority claimed from US13/591,090 external-priority patent/US9255074B2/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015002251A publication Critical patent/MX2015002251A/es
Publication of MX360161B publication Critical patent/MX360161B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta descripción se dirige a: (a) un proceso para preparar compuestos y sales de los mismos que, entre otras cosas, son útiles para inhibir el virus de hepatitis C (VHC); (b) intermediarios útiles para la preparación de los compuestos y sales; (c) composiciones farmacéuticas que comprenden los compuestos o sales; y (d) métodos de uso de tales composiciones.
MX2015002251A 2012-08-21 2013-08-21 Proceso para preparar compuestos antiviricos. MX360161B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/591,117 US8975443B2 (en) 2010-07-16 2012-08-21 Phosphine ligands for catalytic reactions
US13/591,090 US9255074B2 (en) 2010-07-16 2012-08-21 Process for preparing antiviral compounds
PCT/US2013/056061 WO2014031791A1 (en) 2012-08-21 2013-08-21 Process for preparing antiviral compounds

Publications (2)

Publication Number Publication Date
MX2015002251A MX2015002251A (es) 2015-07-06
MX360161B true MX360161B (es) 2018-10-09

Family

ID=50150370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002251A MX360161B (es) 2012-08-21 2013-08-21 Proceso para preparar compuestos antiviricos.

Country Status (6)

Country Link
EP (1) EP2887941B1 (es)
JP (1) JP6469571B2 (es)
CN (1) CN104884440A (es)
CA (1) CA2882624A1 (es)
MX (1) MX360161B (es)
WO (1) WO2014031791A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170003532A (ko) * 2014-03-28 2017-01-09 다우 글로벌 테크놀로지스 엘엘씨 제 1 방향족 화합물을 제 2 방향족 화합물에 커플링시키는 방법
CN106659700B (zh) * 2014-06-06 2020-07-10 斯克里普斯研究所 氟化硫(vi)化合物及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
CN107286061A (zh) * 2017-06-09 2017-10-24 武汉理工大学 一种酚类化合物脱氧还原方法
CN107935802A (zh) * 2017-12-04 2018-04-20 遵义医学院 一种以芳基磺酰氟为原料制备联芳类化合物的方法
CN108218717B (zh) * 2018-01-19 2020-01-07 遵义医科大学 一种利用溴代芳基磺酰氟制备不对称三联苯类化合物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628654A (zh) 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CN102746239B (zh) 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
JP5326510B2 (ja) * 2008-11-11 2013-10-30 セントラル硝子株式会社 α−置換エステル類の製造方法
SG176976A1 (en) * 2009-06-24 2012-02-28 Hoffmann La Roche Heterocyclic antiviral compound
EP3056486B1 (en) * 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds

Also Published As

Publication number Publication date
JP2015526473A (ja) 2015-09-10
JP6469571B2 (ja) 2019-02-13
CA2882624A1 (en) 2014-02-27
EP2887941A1 (en) 2015-07-01
MX2015002251A (es) 2015-07-06
EP2887941A4 (en) 2016-01-27
EP2887941B1 (en) 2018-07-11
CN104884440A (zh) 2015-09-02
WO2014031791A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
MY167881A (en) Process for preparing antiviral compounds
MY201670A (en) Condensed imidazolylimidazoles as antiviral compounds
MX2014013660A (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
NZ727792A (en) Therapeutic compounds
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
NZ631762A (en) 5-membered heteroaryls and their use as antiviral agents
NZ631754A (en) Amide compounds for the treatment of hiv
EP2600835A4 (en) COMBINATIONS OF INHIBITORS OF HEPATITIS C VIRUS
MX2014008227A (es) Inhibidores del virus de la hepatitis c.
TW201240990A (en) Antiviral compounds
PH12013501543A1 (en) Hepatitis c virus inhibitors
MX347692B (es) Inhibidores del virus de la hepatitis c.
PH12013502177A1 (en) Hepatitis c virus inhibitors
MX360161B (es) Proceso para preparar compuestos antiviricos.
PH12015500814A1 (en) Hepatitis c virus inhibitors
MY169288A (en) Process for preparing an antiviral compound
NZ726343A (en) Antiviral compounds
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
PH12013500558A1 (en) Solid state forms of a potent hcv inhibitor
IN2011CH03893A (es)
NZ725365A (en) Antiviral compounds inhibitors of hcv ns5b
TN2013000135A1 (en) Solid state forms of a potent hcv inhibitor
TN2013000335A1 (en) Hepatitis c virus inhibitors
TN2013000453A1 (en) Hepatitis c virus inhibitors
MY163245A (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
FG Grant or registration